Sarcopenia (the loss of muscle mass, strength, and function) is highly prevalent in patients with Chronic Kidney Disease (CKD) undergoing hemodialysis, significantly increasing the risk of falls, frailty, and mortality. Despite its impact, there is a lack of evidence regarding the effectiveness of exercise programs specifically designed to address sarcopenia under the latest international diagnostic criteria (EWGSOP2) in older renal patients. The primary objective of this randomized controlled clinical trial is to evaluate the effects of a 12-week supervised intrahospital exercise program on muscle mass, strength, and physical performance in hemodialysis patients over 40 years of age. Additionally, the study aims to analyze how this intervention influences sleep quality-often disrupted in this population-and overall health-related quality of life. Participants will be randomly assigned to either an Intervention Group, which will perform personalized strength and aerobic exercises during the first 90 minutes of their dialysis sessions, or a Control Group, receiving standard care. Evaluations will be conducted at three points: baseline (pre-randomization), at 12 weeks (post-intervention). The investigators hypothesize that integrating physical exercise into the routine clinical care of hemodialysis patients will improve sarcopenia markers and sleep patterns, leading to greater functional independence and better clinical outcomes.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
58
Personalized intradialytic exercise program performed during the first 30 minutes of the hemodialysis session once the patient is hemodynamically stable. The intervention lasts 12 weeks with 2-3 sessions per week, supervised by physiotherapists. Each session (max. 60 min) includes: 1) Respiratory and joint mobility warm-up; 2) Strength training for lower limbs (hip flexors, extensors, abduction/adduction, and ankle movements) using elastic bands, weighted ankle straps, foam balls, and Pilates rings; 3) Aerobic resistance using a bed-cycle ergometer. Intensity is adjusted progressively to 12-14 on the Borg Scale (range 6-20). The program follows training principles, increasing volume and intensity over time to improve muscle mass, strength, and physical performance.
Universidad de Salamanca
Salamanca, Salamanca, Spain
RECRUITING> Change in Upper Limb Muscle Strength measured by Handgrip Dynamometry.
\> Muscle strength is assessed using a CAMRYR electronic dynamometer (Model EH101). The participant is in a standing position with the arm extended and parallel to the body. Maximum grip strength is measured over 3 seconds. Two attempts are made for each arm, and the highest value from the dominant arm (measured in kilograms) is recorded.
Time frame: > Baseline, 12 weeks (post-intervention)
Change in Lower Limb Muscle Strength measured by the 5-Times Sit-to-Stand Test (STS5).
The STS5 test measures the time (in seconds) required for the patient to rise from a chair 5 consecutive times without arm support. It is a proxy for lower extremity muscle strength and power. A decrease in the time taken indicates an improvement in muscle function.
Time frame: Baseline, 12 weeks (post-intervention)
Change in Appendicular Skeletal Muscle Mass (ASMM) measured by Bioelectrical Impedance Analysis (BIA).
Assessment of body composition and muscle mass using a portable BIA device. This method provides a validated estimate of muscle mass in both ambulatory and bedridden patients. The study focuses on the Appendicular Skeletal Muscle Mass (ASMM), which is essential for confirming a diagnosis of sarcopenia according to EWGSOP2 criteria. Higher values reflect greater muscle mass.
Time frame: Baseline, 12 weeks (post-intervention)
Change in Physical Performance measured by the Short Physical Performance Battery (SPPB).
The SPPB is a composite score (0 to 12 points) evaluating balance, gait speed (4 meters), and the sit-to-stand test. A total score of 8 or less identifies patients with severe sarcopenia or high risk of frailty. Higher scores indicate better physical performance.
Time frame: Baseline, 12 weeks (post-intervention)
Change in Sleep Quality measured by the Pittsburgh Sleep Quality Index (PSQI).
A self-administered questionnaire that assesses sleep quality over a 1-month time interval. It consists of 19 individual items, creating 7 components that yield one global score (range 0 to 21). Lower scores denote better sleep quality.
Time frame: Baseline, 12 weeks (post-intervention)
> Change in Sarcopenia-related Quality of Life measured by the SarQoL® Questionnaire.
\> The Sarcopenia Quality of Life (SarQoL®) is a self-administered questionnaire specifically developed for patients with sarcopenia. It consists of 22 questions covering 55 items across 7 domains: physical and mental health, mobility, body composition, function, activities of daily living, leisure activities, and fears. The total score ranges from 0 to 100, where higher scores indicate a better quality of life.
Time frame: > Baseline, 12 weeks (post-intervention)
Objective Sleep Assessment via Wrist-worn Accelerometry (Actigraph).
Objective measurement of sleep-wake patterns using the Actigraph GT3X+ accelerometer. This device, worn on the wrist for 5 consecutive days, captures continuous data on circadian rhythms and physical activity. Using validated scoring algorithms via Actilife 6 software, the following statistics will be calculated: Total Sleep Time (TST), Sleep Efficiency (percentage of time in bed spent sleeping), and Wake After Sleep Onset (WASO).
Time frame: Baseline, 12 weeks (post-intervention)
Change in Fat Mass Percentage measured by Bioelectrical Impedance Analysis (BIA).
Measurement of the total proportion of body fat relative to total body weight. This parameter is used to evaluate changes in body composition and to identify the presence of sarcopenic obesity in hemodialysis patients. A decrease in fat mass percentage is generally associated with improved metabolic health in this population.
Time frame: Baseline, 12 weeks (post-intervention).
Change in Total Body Water (TBW) Percentage measured by Bioelectrical Impedance Analysis (BIA).
Evaluation of the percentage of total body water, including intracellular and extracellular compartments. In hemodialysis patients, this measure is crucial to ensure that changes in muscle mass measurements are not confounded by variations in hydration status or fluid overload between sessions.
Time frame: Baseline, 12 weeks (post-intervention).
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.